Concord Biotech Ltd

Concord Biotech Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Concord Biotech Ltd

₹ 1,507 -0.12%
13 May - close price
concordbiotech.com BSE: 543960 NSE: CONCORDBIO
About

Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]

Key Points

Busines segments
A) APIs[1] Co manufactures API's through fermentation and semi-synthetic processes, across therapeutic areas of immunosuppressants, oncology, and anti-infectives
B) Formulations[2] which are used in therapeutic areas of immunosuppressants, nephrology and anti-infective drugs for critical care.

Website BSE NSE
  • Market Cap ₹ 15,759 Cr.
  • Current Price ₹ 1,507
  • High / Low ₹ 1,725 / 900
  • Stock P/E 51.7
  • Book Value ₹ 129
  • Dividend Yield 0.00 %
  • ROCE 26.4 %
  • ROE 19.8 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Stock is trading at 11.6 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
181 159 241 273 195 262 241
116 121 131 146 123 147 135
Operating Profit 65 37 110 127 72 116 106
OPM % 36% 24% 46% 47% 37% 44% 44%
14 6 9 12 13 8 11
Interest 1 1 1 1 1 1 0
Depreciation 14 13 14 14 13 13 14
Profit before tax 64 30 105 124 71 110 103
Tax % 23% 26% 26% 26% 23% 26% 25%
49 22 77 91 54 81 78
EPS in Rs 51.79 2.10 7.40 8.75 5.21 7.74 7.41
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
512 616 713 853 971
308 289 443 504 550
Operating Profit 205 327 270 349 421
OPM % 40% 53% 38% 41% 43%
32 14 23 37 44
Interest 1 1 6 10 4
Depreciation 21 28 50 54 54
Profit before tax 214 313 238 322 407
Tax % 21% 25% 26% 25%
169 235 175 240 305
EPS in Rs 177.81 247.44 183.93 22.95 29.11
Dividend Payout % 22% 0% 3% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 19%
TTM: 20%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 16%
TTM: 39%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 20%
Last Year: 20%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 10 10 10 10 10
Reserves 761 990 1,094 1,280 1,344
52 86 62 32 23
118 97 147 192 174
Total Liabilities 941 1,183 1,313 1,514 1,551
240 546 573 593 590
CWIP 141 18 74 173 188
Investments 199 141 74 137 151
361 477 592 611 621
Total Assets 941 1,183 1,313 1,514 1,551

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023
155 207 246
-114 -112 -158
-43 -100 -85
Net Cash Flow -1 -4 3

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 131 105 119 117
Inventory Days 312 503 434 430
Days Payable 201 152 185 190
Cash Conversion Cycle 242 456 368 357
Working Capital Days 160 180 177 163
ROCE % 32% 21% 26%

Shareholding Pattern

Numbers in percentages

4 Recently
Sep 2023Dec 2023Mar 2024
44.08% 44.08% 44.08%
7.30% 7.00% 6.49%
8.12% 8.40% 8.41%
40.50% 40.52% 41.03%
No. of Shareholders 1,00,92787,48683,296

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

No data available.

DRHP

Credit ratings

Concalls